# Treatments for Parkinson's Disease
The treatment of Parkinson's disease focuses on relieving symptoms and maintaining quality of life. There are no treatments that stop the underlying damage to brain cells, but there are various approaches that can reduce movement problems, stiffness, and tremor. The choice of treatment depends on the stage of the disease, which symptoms are most bothersome, and how someone has responded to previous medications.
Medications that supplement or replace dopamine
**Levodopa (L-DOPA)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Levodopa is the most effective medication for the movement symptoms of Parkinson's disease. The body converts levodopa into dopamine, a substance that decreases in quantity in people with Parkinson's. Because dopamine cannot directly reach the brain, levodopa is used as a replacement. In the early stages, many people with smaller doses can already feel considerable relief from rigidity and slowness. As the disease progresses, the duration of effectiveness of each dose can become shorter, leading to fluctuating periods of better and worse functioning ('on-off fluctuations').
Known side effects include nausea (especially at the beginning), movement disorders (choreoathetosis) after prolonged use, drowsiness, and in general the same adverse effects as other dopamine replacers: low blood pressure when standing up, hallucinations in later stages, and impulsive behavior. These effects vary greatly from person to person.
**Dopamine agonists (including pramipexole, ropinirole, rotigotine)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Dopamine agonists mimic the action of dopamine in the brain. They are used especially in the early stage, sometimes alone and later in combination with levodopa. They can reduce tremor and stiffness, albeit usually less powerfully than levodopa. The advantage is that they do not immediately 'wear off' like levodopa can after several years.
Side effects partially overlap with those of levodopa: nausea, drowsiness, low blood pressure, hallucinations. A particular concern is the risk of impulsive behavior (gambling, online shopping, uncontrolled eating) in some users, especially at higher doses. Ankle swelling and reduced alertness can also occur.
**Catechol-O-methyltransferase inhibitors (COMT inhibitors)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications (entacapone is the most commonly used) extend the duration of action of levodopa by slowing its breakdown in the body. They are usually used in combination with levodopa, especially when someone becomes less stable and symptoms fluctuate more. They do not add their own dopamine action, but 'stretch' the effect of each dose of levodopa.
Side effects are minor, but can include diarrhea, dark urine, and increased heart rate.
**Monoamine oxidase B inhibitors (MAO-B inhibitors, for example selegiline, rasagiline)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
MAO-B inhibitors inhibit the natural breakdown process of dopamine in the brain. They can be used especially in the early stage as a single treatment, or later together with levodopa or dopamine agonists. The effect is usually moderate, but some studies suggest that they may possibly slow the progression of the disease, although this has not been definitively proven.
Side effects are usually minor. In combination with certain other medications (particularly certain antidepressants and opiates), risk situations can arise.
Medications targeting non-motor symptoms
**Anticholinergics (for example benztropine)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications work against tremor and stiffness by inhibiting another neurotransmitter system (acetylcholine). They are given less often than in the past, because they are less effective than levodopa and have stronger side effects. However, they can be useful in the early stage when tremor is dominant.
Side effects are quite numerous: blurred vision, dry mouth, constipation, urination problems, confusion and memory problems, especially in older people.
**Antidepressants**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many people with Parkinson's experience depression and anxiety. Selective serotonin reuptake inhibitors (SSRIs) and certain other antidepressants are prescribed to address these mood disorders. This does not directly improve movement problems, but does contribute to quality of life.
Side effects depend on the type of antidepressant, but include fatigue, sexual dysfunction, and sometimes initial worsening of anxiety.
**Medications for insomnia and sleepiness**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many people with Parkinson's suffer from nightmares, restless sleep, insomnia, or excessive daytime sleepiness. Sleep-related problems are treated based on what exactly the problem is (night awakenings, troubled nighttime sleep, sudden daytime sleep onset). Various medications and approaches can help.
**Medications for gastrointestinal and bladder disorders**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Constipation and difficulty urinating are very common in Parkinson's. These can be a direct result of the disease itself, or of the medications. Laxatives, fluid intake, and certain medications (for example domperidone for gastrointestinal disorders) are used. Constipation medications are especially important because severe constipation can interfere with the absorption of Parkinson's medications.
Movement therapy and rehabilitation
**Physiotherapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular guided movement therapy helps keep muscles flexible, counteracts balance changes and falling tendencies, and maintains mobility longer. This works better the earlier in the disease it begins. Physiotherapy does not replace medication, but supplements it: training helps maintain independence and reduce fall risk.
**Speech therapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many people with Parkinson's develop speech problems (soft, monotone voice) and swallowing difficulties (dysphagia). Speech therapy training can improve speech clarity and support safe eating and drinking. This is especially important because swallowing difficulties lead to choking, malnutrition, and pneumonia.
Surgical treatments
**Deep brain stimulation (DBS)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
DBS is an operation in which thin electrode wires are placed in specific brain areas to stimulate them with regular impulses. This can provide significant relief from tremor, rigidity, and slowness, especially in the middle to advanced stages. It is not suitable for everyone: it helps especially those whose symptoms still respond well to levodopa, but where medications became less stable.
The procedure requires thorough pre-selection and repeated adjustments after implantation. Side effects include infection, bleeding during surgery, speech and behavior changes, and technical defects of the device.
**Pallidotomy and thalamotomy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These are older surgical techniques in which brain tissue is destroyed (ablated). They are used much less frequently nowadays because DBS generally works better and is reversible. They may still occur in patients who cannot have DBS.
Complementary therapeutic approaches
**Physical activity and exercise programs (including dance, tai chi)**
ResearchediPositive results in clinical studies, not yet standard treatment
Different forms of regular movement (dance, swimming, yoga, tai chi) show positive effects on balance, gait, and quality of life. It is not entirely clear whether this slows disease progression, but it clearly contributes to maintaining mobility and mental well-being. These approaches are more a supplement than a replacement for medications.
**Vagus nerve stimulation (VNS)**
ResearchediPositive results in clinical studies, not yet standard treatment
Recent research is examining whether stimulating the vagus nerve (via electrodes or non-invasive methods) can improve Parkinson's symptoms. This is not yet included in standard treatment, but is being investigated in clinical trials because of the connection between nervous system and immune regulation.
**Urolithin A**
ResearchediPositive results in clinical studies, not yet standard treatment
Urolithin A is a substance from certain food components that showed neuroprotective effects against Parkinson-like damage in laboratory studies. The research is still very early and experimental; there is no evidence of effectiveness in people with Parkinson's.
**Cannabidiol (CBD)**
ResearchediPositive results in clinical studies, not yet standard treatment
In laboratory settings, CBD (a component of cannabis without psychoactive effects) shows possible neuroprotective effects against certain forms of cell damage. In people with Parkinson's, evidence is still very limited. It is being investigated in a number of clinical studies, particularly for non-motor symptoms such as anxiety and insomnia.
Experimental directions
**Immunomodulators**
ExperimentaliOngoing in study setting, outcome still unknown
Because research suggests that inflammation and immune changes play a role in Parkinson's, researchers are looking at agents that can restore immune protection or inhibit inflammatory processes. This is not yet in clinical use, but is being studied in trials.
**Gene therapy**
ExperimentaliOngoing in study setting, outcome still unknown
In research stages, possibilities are being explored to use gene editing to produce more dopamine in brain regions or prevent cell damage. This is still very experimental and not available outside of specialized research.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._